Sam Brusco, Associate Editor05.03.24
Elekta has launched Evo, a CT-Linac with new, high-definition artificial intelligence (AI)-enhanced imaging. It was introduced at this year’s Annual Congress of the European Society for Radiotherapy and Oncology (ESTRO 2024).
Evo can deliver offline and online adaptive radiation therapy, as well as improved standard image-guided radiation therapy. Elekta said the hightly versatile CT-Linac will help clinicians choose the best therapy technique for each individual patient. It has CE mark certification and isn’t available in all markets.
The CT-Linac touts powerful AI capabilities and anatomy-specific algorithms. Its proprietary Iris high-definition imaging helps to precisely visualize target areas, and increase automation and speed, according to the company.
Elekta ONE Planning, a new extension of the company’s software portfolio powered by MIM, is also included in the treatment planning. It provides faster dose calculation and AI-driven automation for contouring and dose planning. It also supports both Elekta and non-Elekta devices including proton therapy.
“We are very excited to introduce an adaptive CT-Linac that is designed from our commitment to delivering groundbreaking image guided radiation therapy technology,” said Elekta CEO Gustaf Salford. “Elekta Evo truly brings hope for more precise, personalized and effective care, which will benefit all those who deal with cancer. Once again, Elekta demonstrates dedication to accelerate innovation in cancer care.”
“Evo is an incredibly versatile linac that—in the era of increasingly stretched resources—will give our customers the freedom to adopt new technologies at their own pace,” added Maurits Wolleswinkel, Elekta’s president of Linac and software solutions. “With the recently announced treatment planning enhancements to our Elekta ONE software suite, we now have a comprehensive offering for increased personalization as well as versatility that can take radiation therapy to the next level.”
The company also recently acquired the patent portfolio for Philips’ Pinnacle treatment planning system.
Evo can deliver offline and online adaptive radiation therapy, as well as improved standard image-guided radiation therapy. Elekta said the hightly versatile CT-Linac will help clinicians choose the best therapy technique for each individual patient. It has CE mark certification and isn’t available in all markets.
The CT-Linac touts powerful AI capabilities and anatomy-specific algorithms. Its proprietary Iris high-definition imaging helps to precisely visualize target areas, and increase automation and speed, according to the company.
Elekta ONE Planning, a new extension of the company’s software portfolio powered by MIM, is also included in the treatment planning. It provides faster dose calculation and AI-driven automation for contouring and dose planning. It also supports both Elekta and non-Elekta devices including proton therapy.
“We are very excited to introduce an adaptive CT-Linac that is designed from our commitment to delivering groundbreaking image guided radiation therapy technology,” said Elekta CEO Gustaf Salford. “Elekta Evo truly brings hope for more precise, personalized and effective care, which will benefit all those who deal with cancer. Once again, Elekta demonstrates dedication to accelerate innovation in cancer care.”
“Evo is an incredibly versatile linac that—in the era of increasingly stretched resources—will give our customers the freedom to adopt new technologies at their own pace,” added Maurits Wolleswinkel, Elekta’s president of Linac and software solutions. “With the recently announced treatment planning enhancements to our Elekta ONE software suite, we now have a comprehensive offering for increased personalization as well as versatility that can take radiation therapy to the next level.”
The company also recently acquired the patent portfolio for Philips’ Pinnacle treatment planning system.